KYSE-150-luc Orthotopic Mouse Model Service for Esophageal Cancer

The KYSE-150-luc orthotopic mouse model implants luciferase-labeled human esophageal squamous carcinoma cells into the esophageal wall of immunodeficient mice, creating an optically traceable tumor that grows where the disease naturally occurs. Alfa Cytology provides this model as a turnkey preclinical service—managing authenticated reporter cell banks, orthotopic microsurgery, serial bioluminescence imaging, randomized dosing arms, and complete histopathological endpoints—so sponsors obtain publication-quality, longitudinally quantified data without investing in their own surgical and imaging infrastructure.

Overview of KYSE-150-luc Orthotopic Mouse Model for Esophageal Cancer

The KYSE series, established at the Kyoto Prefectural University of Medicine in the early 1990s, was the first large panel of esophageal squamous cell carcinoma lines systematically characterized for the international research community, and KYSE-150 remains one of its most widely used members. Labeling this line with firefly luciferase converts it into a sensor-equipped tumor: once cells are implanted into the esophageal wall, the emitted photon flux after D-luciferin administration reports viable tumor burden at each imaging session. This matters enormously in orthotopic esophageal work, because the esophagus is inaccessible to calipers, and intermittent sacrifice cohorts would otherwise be the only way to chart tumor growth. With the luciferase reporter, each animal becomes a self-contained time course, and subtle differences between treatment arms—delayed onset, slowed doubling, partial regression, or early relapse—become visible weeks before they would affect survival.

Fig 1. Image of poorly differentiated KYSE150 orthotopic tumor indicates invasion from mucosa to adventitia and with lymphovascular permeation in the mouse esophagus at week 4. (Ip, Joseph Chok Yan, et al., 2015)

Biologically, KYSE-150 offers a distinctive genetic landscape: the line carries high-level amplification of EGFR-family and cyclin D1 loci, a truncating homozygous TP53 mutation, and p16 silencing by promoter methylation, making it a relevant backdrop for studies of cell-cycle-targeted agents, EGFR-pathway inhibitors, DNA-damage response, and epigenetic therapy. Its documented ability to form tumorspheres with enriched stemness markers further connects it to research on tumor-initiating populations and radioresistance. In the orthotopic setting, the KYSE-150-luc model has been applied to agent efficacy ranking, combination regimens, molecular perturbation studies—where gene knockdown or overexpression is monitored through imaging trajectories—and investigations of metastatic behavior. Both in vitro and in vivo data accumulated on this background over three decades give sponsors an unusually rich comparator literature against which new results can be benchmarked.

Cell Line Information: KYSE-150-luc

KYSE-150-luc is the luciferase reporter derivative of KYSE-150, a poorly differentiated ESCC line established in 1992 by Shimada and colleagues from a resected cervical-esophageal tumor of a 49-year-old Japanese woman who had received radiotherapy; the primary tumor was described as invading contiguous structures. The parental line is distributed by major repositories including DSMZ (ACC 375) and JCRB (JCRB1095), is a member of the Cancer Cell Line Encyclopedia, and is extensively characterized genetically and pharmacologically. Reporter labeling is achieved by stable integration of the firefly luciferase cassette, preserving the growth and tumorigenic properties of the parental line while adding optical quantifiability in vivo. Key attributes are summarized below.

Our Services

Few contract research environments combine validated luciferase reporter lines with the microsurgical dexterity the esophagus demands—and even fewer can run both under one quality system. Alfa Cytology closes that gap: we bank STR-authenticated, mycoplasma-free KYSE-150-luc cells, titrate inoculum through pilot engraftment runs when needed, execute orthotopic implantation under aseptic conditions, acquire scheduled bioluminescence images, administer test articles, and close out with ex vivo organ imaging, tumor metrics, and H&E/immunohistochemistry—all documented in a single audit-ready report.

Workflow of KYSE-150-luc Orthotopic Mouse Model Construction

Model construction integrates reporter cell qualification, orthotopic delivery into the esophageal wall, and longitudinal optical follow-up. Inoculum size (typically in the range of 1–5 × 10⁶ cells), carrier composition, and imaging cadence are confirmed with each sponsor during study design and validated in a pilot engraftment run when timelines allow.

1. Reporter cell bank release: KYSE-150-luc vials are revived from the working bank, screened for mycoplasma, confirmed by STR profiling, and functionally validated for luciferase signal linearity across cell numbers.
2. Inoculum preparation: Log-phase cells are harvested by trypsinization, counted, and suspended with Matrigel or an equivalent carrier to retain the bolus at the injection site.
3. Mouse preparation and randomization: Female BALB/c nude mice complete quarantine and acclimatization, then are randomized into cohorts balanced for body weight.
4. Anesthesia and surgical exposure: Under general anesthesia with perioperative analgesia, a small upper abdominal incision exteriorizes the stomach and exposes the distal esophagus.
5. Orthotopic inoculation: A fine-gauge needle deposits the cell suspension into the esophageal wall; a transient pale bleb confirms intramural placement before layered closure of the incision.
6. Postoperative care: Animals recover on warming pads and are monitored daily for weight, feeding, and incision healing until fully recovered.
7. Serial bioluminescence imaging: After intraperitoneal D-luciferin injection, whole-body photon flux is quantified at scheduled intervals to map engraftment, exponential growth, and treatment response.
8. Endpoint and tissue analysis: At protocol endpoints, mice are euthanized; the esophagus, draining lymph nodes, and organs are imaged ex vivo, then processed for tumor measurement, H&E, and immunohistochemistry.

Fig 2. KYSE-150-luc orthotopic mouse model construction workflow.

Case Study-KYSE-150-luc Orthotopic Mouse Model Development

KYSE-150-luc orthotopic studies are an established component of Alfa Cytology’s esophageal cancer service portfolio. In a representative preclinical program, our scientists established reproducible orthotopic tumors from authenticated reporter cells, verified intramural engraftment through serial imaging, and supported randomized efficacy cohorts in which bioluminescence trajectories separated treatment groups weeks ahead of terminal readouts. End-of-study histopathology confirmed tumor location, growth pattern, and esophageal wall involvement. Representative datasets from this program can be provided upon request under confidentiality.

Why Choose Alfa Cytology?

The KYSE-150-luc orthotopic model rewards precision at every step, and Alfa Cytology is organized to deliver exactly that—authenticated reagents, disciplined surgery, and imaging-driven study execution under one roof.

• Authenticated reporter banks: every KYSE-150-luc lot is STR-verified, mycoplasma-screened, and checked for luciferase linearity.
• Microsurgical reliability: standardized esophageal wall implantation with visual confirmation of intramural delivery.
• Longitudinal quantification: scheduled bioluminescence imaging converts each animal into a complete time-course dataset.
• Design flexibility: inoculum titration, group sizes, dosing routes, and endpoints configured to sponsor protocols.
• Full-spectrum endpoints: ex vivo organ imaging, tumor metrics, body weight records, and H&E/IHC in organized reports.
• Single-point accountability: one dedicated project scientist coordinates scheduling, interim updates, and final delivery.

Contact Us

If your esophageal cancer program needs an orthotopic model you can quantify week by week, our scientists are ready to design the right KYSE-150-luc study for you—reach out to discuss readouts, timelines, and cohort structure. Contact us today, and let Alfa Cytology put a measurable orthotopic tumor to work for your next preclinical decision.

For research use only. Not intended for any clinical use.